The hypertension clinical trial analysis report delivers important insights into ongoing research of 24+ pipeline hypertension drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

New York, USA, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s 'Hypertension Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for hypertension across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the hypertension domain.

Hypertension Clinical Trial Analysis Summary

DelveInsight’s hypertension pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline hypertension drugs.
Key hypertension companies, such as Gossamer Bio, Chiesi USA, Inc., Alnylam Therapeutics, Roche, Quince Therapeutics, GSK plc., CalciMedica, Suzhou Sanegene Bio Inc., Innovent Biologics, Inc., Insmed Incorporated, Novartis Pharmaceuticals, Vascarta, NS Pharma, Inc., Regeneron Pharmaceuticals, Apollo Therapeutics, 35Pharma Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Vanda Pharmaceuticals, ADARx Pharmaceuticals, Inc., and others, are evaluating new hypertension drugs to improve the treatment landscape.
Promising pipeline hypertension therapies, such as Seralutinib, Zilebesiran, LAM-001, GSK6792070, CM5480, SGB 3908, Treprostinil Palmitil, QCZ 484, VAS-101, NS-863, REGN13335, APL-9796, HS235, MN-08, Iloperidone, ADX-850, and others, are in different phases of hypertension clinical trials.
Approximately 40+ hypertension drugs are in the late stages of development.
Notable MoAs in hypertension clinical trials include PDGFR inhibitor, CSF1R inhibitor, c-KIT inhibitors, Angiotensinogen expression inhibitors, RNA interference, Epoprostenol receptor agonists, Platelet aggregation inhibitors, Methylmalonyl CoA mutase stimulants, MTOR protein inhibitors, Activin signaling inhibitors, CRAC channel inhibitors, Dopamine D2 receptor antagonists, Serotonin 5-HT2 receptor antagonists and others.

Request a sample and discover the recent advances in hypertension treatment @ https://www.delveinsight.com/report-store/hypertension-pipeline-insight

What is Hypertension?

Hypertension, commonly known as high blood pressure, is a chronic medical condition in which the force of blood against the walls of the arteries remains consistently higher than normal. It develops when the heart pumps blood with excessive force or when the blood vessels become narrowed or less flexible, increasing resistance to blood flow. Often referred to as a “silent” condition because it may not cause noticeable symptoms, hypertension can progressively damage vital organs and increase the risk of serious complications, including heart disease, stroke, kidney disease, and other cardiovascular disorders. Regular blood pressure monitoring and appropriate lifestyle modifications and medical management are important for controlling blood pressure and reducing the risk of long-term complications.

Find out more about treatment for hypertension @ Hypertension New Treatment

A snapshot of the Pipeline Hypertension Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
Seralutinib	Gossamer Bio/CHIESI USA, Inc.	III	PDGFR, CSF1R, c-KIT inhibitors	Inhalation
Zilebesiran	Alnylam Therapeutics/ Roche	III	Angiotensinogen expression inhibitor, RNA interference	SC
Treprostinil Palmitil	Insmed Incorporated	III	Epoprostenol receptor agonists; Platelet aggregation inhibitors	Inhalation
LAM-001	Quince Therapeutics	II	Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors	Inhalation
SGB 3908	Suzhou Sanegene Bio Inc./Innovent Biologics, Inc.	II	Angiotensinogen expression inhibitor, RNA interference	SC
GSK6792070	GSK plc.	I/II	Activin signaling inhibitor	SC
CM5480	CalciMedica	Preclinical	CRAC channel inhibitor	Oral

Learn more about the hypertension research @ Hypertension Clinical Trials

Stuti Mahajan, consulting manager at DelveInsight, said that the hypertension treatment landscape is evolving beyond conventional antihypertensive therapies, with increasing development of novel mechanisms and longer-acting treatment approaches focused on uncontrolled and resistant hypertension, treatment adherence, and cardiovascular-risk reduction. The pipeline reflects growing diversification, including RNA-interference therapies targeting angiotensinogen, activin-signaling inhibition, emerging oral therapies, and pulmonary vascular-targeted approaches, while lorundrostat represents a leading opportunity among novel conventional antihypertensive agents. The advancement of zilebesiran and other mechanism-specific therapies highlights the potential of durable and infrequently administered treatments to improve adherence and sustained blood-pressure control, although clinical setbacks with emerging agents demonstrate the challenges of translating novel mechanisms into meaningful outcomes. Overall, the hypertension market outlook remains positive, with future commercial success likely to depend on durable efficacy, cardiovascular and renal outcomes, safety, adherence benefits, and clear differentiation from established low-cost generic therapies.

Recent Developments in Hypertension Treatment Space

In August 2026, Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), announced that it has entered into a securities purchase agreement with certain new and existing institutional investors for a private placement financing expected to provide aggregate gross proceeds of up to approximately USD 250 million, before deducting placement agent fees and estimated offering expenses. The private placement consists of an initial closing, a committed second closing contingent upon FDA acceptance of the seralutinib new drug application (NDA) in PAH (the NDA Acceptance Milestone) and warrants exercisable upon FDA approval of seralutinib in PAH (the FDA Approval Milestone). The financing follows the Company’s recent reacquisition of worldwide rights to seralutinib and is in advance of the planned NDA submission in September 2026.
In June 2026, CRISPR Therapeutics mentioned in its second quarter financial results that CTX340™, targeting angiotensinogen (AGT), received IND clearance from the FDA. The Company has initiated a Phase I clinical trial for patients with refractory hypertension.
In May 2026, CalciMedica in its second quarter financial results provided an update, that studies are ongoing to further characterize the pharmacology, pharmacokinetics, and safety profile of CM5480, a proprietary oral CRAC channel inhibitor candidate with the potential to be a first-in-class, differentiated therapy targeting pulmonary vascular and right ventricular remodeling, key drivers of disease progression in PH, including pulmonary arterial hypertension. An IND submission for CM5480 is anticipated in 2027.
In May 2026, Mineralys Therapeutics, Inc. presented new clinical data for lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) in Gdańsk, Poland. The analysis evaluated the efficacy and safety of once-daily lorundrostat 50 mg by CKD status among 800 participants with uncontrolled or resistant hypertension enrolled in the randomized, double-blind, placebo-controlled Phase III Launch-HTN trial. Among participants with CKD (n=192), 71% were receiving three or more anti-hypertensive medications at baseline, compared with 56% of those without CKD. In addition, 31% of participants with CKD had systolic blood pressure (SBP) ≥160 mmHg at baseline, versus 17% of participants without CKD. Lorundrostat demonstrated significant reductions in SBP that were comparable between CKD and non-CKD participants. At week 12, placebo-adjusted SBP reductions were 9.6 mmHg in participants with CKD (p=0.0022) and 12.2 mmHg in those without CKD (p<0.0001). A greater proportion of lorundrostat-treated participants also achieved target SBP of <130 mmHg at week 12 compared with placebo, both among CKD participants (44% vs 18%) and non-CKD participants (48% vs 22%).
In April 2026, AllRock Bio, Inc. announced the dosing of the first patients in the Phase IIa ROCSTAR trial of ROC-101, a first-in-class, oral pan-rho-associated protein kinase (ROCK) inhibitor, in pulmonary hypertension (PH). Building on Phase I data, the open-label, multicenter, exploratory study will evaluate the safety, tolerability, and efficacy of ROC-101 to treat patients with pulmonary arterial hypertension (PAH) or PH associated with interstitial lung disease (ILD-PH).
In March 2026, Kardigan, a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, announced results from KARDINAL, a Phase II clinical trial evaluating the effects of tonlamarsen in patients with uncontrolled hypertension despite treatment with two or more antihypertensive medications. Data were presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.26) and simultaneously published in The Journal of the American College of Cardiology (JACC). In the clinical trial, tonlamarsen, an investigational antisense oligonucleotide (ASO) targeting angiotensinogen (AGT), demonstrated a statistically significant reduction in plasma AGT levels and a clinically meaningful reduction in in-office systolic blood pressure (oSBP) from baseline to Week 20. These results highlight the intended biological effect of tonlamarsen and support evaluation in Kardigan’s planned Phase IIb clinical trial in patients with acute severe hypertension (ASH) post-hospitalization.
In March 2026, Mineralys Therapeutics, Inc. announced that the FDA has accepted the New Drug Application (NDA) for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026.
In February 2026, GSK plc announced that it has entered an agreement to acquire 35Pharma Inc., a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics. The acquisition includes HS235, a potential best-in-class investigational medicine that has completed phase I healthy volunteer clinical trials with studies to start imminently in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).
In October 2025, Alnylam Pharmaceuticals, Inc. announced that the first patient has been dosed in ZENITH (ZilebEsiraN CardIovascular OuTcome Study in Hypertension), a global Phase III cardiovascular outcomes trial (CVOT) designed to evaluate the potential of zilebesiran, an investigational biannual subcutaneously administered RNAi therapeutic, to reduce the risk of major adverse cardiovascular (CV) events in patients with uncontrolled hypertension. Zilebesiran works by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts CV and renal health.
In August 2025, Roche and Alnylam announced the decision to initiate a Phase III cardiovascular outcomes trial (CVOT) to evaluate the ability of zilebesiran, a RNAi therapeutic, to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension. This decision was informed by the comprehensive KARDIA Phase II programme, including KARDIA 1, KARDIA 2 and the most recent KARDIA-3 study evaluating the efficacy and safety of zilebesiran in patients with uncontrolled hypertension and high cardiovascular (CV) risk, on two to four standard of care antihypertensives. In particular, KARDIA-3 aimed to define the patient population to be investigated in the Phase III CV outcomes trial.
In March 2025, Mineralys Therapeutics, Inc. announced positive topline data from its pivotal Launch-HTN Phase III and pivotal Advance-HTN Phase II trials evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN). Both trials successfully achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints and demonstrated a favorable safety and tolerability profile.

Scope of the Hypertension Pipeline Report

Coverage: Global
Hypertension Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Hypertension Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Hypertension Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
Hypertension Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
Hypertension Therapeutics Assessment By Mechanism of Action: PDGFR, CSF1R, c-KIT inhibitors, Angiotensinogen expression inhibitor, RNA interference, Epoprostenol receptor agonists, Platelet aggregation inhibitors, Methylmalonyl CoA mutase stimulants, MTOR protein inhibitors, Activin signaling inhibitor, CRAC channel inhibitor, and others
Key Hypertension Companies: Gossamer Bio, Chiesi USA, Inc., Alnylam Therapeutics, Roche, Quince Therapeutics, GSK plc., CalciMedica, Suzhou Sanegene Bio Inc., Innovent Biologics, Inc., Insmed Incorporated, Novartis Pharmaceuticals, Vascarta, NS Pharma, Inc., Regeneron Pharmaceuticals, Apollo Therapeutics, 35Pharma Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Vanda Pharmaceuticals, ADARx Pharmaceuticals, Inc., and others.
Key Hypertension Pipeline Therapies: Seralutinib, Zilebesiran, LAM-001, GSK6792070, CM5480, SGB 3908, Treprostinil Palmitil, QCZ 484, VAS-101, NS-863, REGN13335, APL-9796, HS235, MN-08, Iloperidone, ADX-850, and others.

Dive deep into rich insights for hypertension cure, visit @ Hypertension News

Table of Contents

1.	Hypertension Pipeline Report Introduction
2.	Hypertension Pipeline Report Executive Summary
3.	Hypertension Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Hypertension Clinical Trial Therapeutics
6.	Hypertension Pipeline: Late-Stage Products (Pre-registration)
7.	Hypertension Pipeline: Late-Stage Products (Phase III)
8.	Hypertension Pipeline: Mid-Stage Products (Phase II)
9.	Hypertension Pipeline: Early-Stage Products (Phase I)
10.	Hypertension Pipeline Therapeutics Assessment
11.	Inactive Products in the Hypertension Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Hypertension Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the hypertension clinical trials, reach out @ Hypertension Medication

Related Reports

Hypertension Market

Hypertension Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hypertension companies, including H Lundbeck A/S, Brain Neurotherapy Bio, Inc., Asklepios BioPharmaceutical, Inc., Theravance Biopharma, Ono Pharmaceutical Co. Ltd, Ionis Pharmaceuticals, Inc., Biogen, Alterity Therapeutics, Teva Pharmaceutical, MODAG GmbH, and others.

Pulmonary Hypertension Market

Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key pulmonary hypertension companies, including Tenax Therapeutics, Inc., Tectonic Therapeutic, OrphAI Therapeutics, Pharmosa Biopharm Inc., United Therapeutics, Pfizer, Attgeno AB, Cumberland Pharmaceuticals, Pulmovant, Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Foresee Pharmaceuticals Co., Ltd., Novartis Pharmaceuticals, ABLi Therapeutics, Inc., 35Pharma Inc., Beijing Continent Pharmaceutical Co, Ltd., Keros Therapeutics, Inc., Bayer, AstraZeneca, Apollo Therapeutics Ltd, and others.

Chronic Pulmonary Hypertension Market

Chronic Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic pulmonary hypertension companies, including Bayer, Attgeno AB, Cereno Scientific AB, Bial - Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie, Tenax Therapeutics, Insmed, Altavant Sciences, and others.

Pulmonary Arterial Hypertension Market

Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key PAH companies, including United Therapeutics, Respira Therapeutics, Gossamer Bio, Liquidia Technologies, Pharmosa Biopharm, Insmed Incorporated, Cereno Scientific, AllRock Bio, Inhibikase Therapeutic, and others.

Chronic Thromboembolic Pulmonary Hypertension Market

Chronic Thromboembolic Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CTEPH companies, including SciPharm Sarl, BAYER, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

CONTACT: Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679